From The Editor
-
Companies To Watch: Vivani Medical
5/30/2025
Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant.
-
Promoting A Newly Approved Indication Against Established Competitors
5/14/2025
In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.
-
Building Uniquity Bio: Teams, Capital, And Strategy
4/30/2025
Brian Lortie, president and CEO at Uniquity Bio, offered up key insights on building teams, securing capital, and operating with efficiency during a recent Business of Biotech podcast recording.
-
Amgen's Ian Thompson On Leadership And A Global Mindset
4/8/2025
Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's learned from working in global markets, and key pipeline highlights.
-
A CEO With A General Counsel's Perspective
2/28/2025
LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous perspective on the CEO role.
-
FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance
2/21/2025
Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order. That doesn't mean biopharmaceutical companies can backslide on compliance in global markets.
-
FDA's Psychedelic Reckoning
11/27/2024
Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS Secretary could be a win for psychedelic drug developers.
-
CEO Panel Talks IRA Impact At Galien Forum
11/14/2024
A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far, and what's likely to come in the year ahead.
-
A Bioethicist Weighs In On Obesity Drugs
10/31/2024
Anne Zimmerman, editor-in-chief of the Columbia University online journal, Voices in Bioethics discusses her concerns over the use of GLP-1 weight loss drugs in the U.S.
-
New Leadership At The Cancer Research Institute
9/27/2024
Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year old cancer research nonprofit into the future.